Page 4 - Nasdaq Rlmd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The Manufacturers Life Insurance Company lowered its position in Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) by 17.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 25,037 shares of the company’s stock after selling 5,393 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Relmada Therapeutics were worth $89,000 at the […]

Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) have earned an average rating of “Hold” from the seven ratings firms that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target […]

Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) have received an average recommendation of “Hold” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12-month […]

Apricus wealth LLC lowered its stake in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) by 28.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 77,329 shares of the company’s stock after selling 30,000 shares during the quarter. apricus wealth LLC owned approximately […]

Relmada Therapeutics (NASDAQ:RLMD – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company. The Company is developing LevoCap ER, an abuse resistant, once-a-day sustained release […]